Treatment of Hepatitis B in Resource-limited Settings

Status Active, not recruiting

Clinical Trial Summary

Viral hepatitis kills nearly one million people each year, even though effective treatment exists. The aim of this study is to establish a treatment protocol for hepatitis B, which is simple and cheap enough to be implemented in resource-limited settings.

Clinical Trial Description

Chronic viral hepatitis is a major health problem globally. Each year nearly one million deaths are attributable to either hepatitis B or C. In Ethiopia 5-10% of the general population are infected with hepatitis B. Oral antiviral treatment of hepatitis B exists, but high costs and advanced laboratory requirements have been barriers to offer such treatment in resource-limited settings, resembling the situation in treatment of HIV/AIDS a decade ago. The present study will investigate a simplified approach to hepatitis B treatment in resource-limited settings, inspired by the recent success of HIV treatment in such settings. The critical research question is how to identify patients with expected benefit of treatment in the absence of advanced laboratory support. A WHO expert panel recently suggested treatment criteria for use in settings without advanced laboratory facilities, but these criteria have not yet been tested out in real life. The present study will build on and develop the WHO approach to treatment of hepatitis B, aiming to develop a treatment protocol that can be feasible in other resource-limited countries. The potential public health benefit for poor people in low- and middle-income countries is substantial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02344498
Study type	Observational
Source	Oslo University Hospital
Contact
Status	Active, not recruiting
Phase
Start date	January 2015
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01182311` - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed	`NCT04971928` - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment	Phase 1
Completed	`NCT03285620` - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants	Phase 1
Completed	`NCT01884415` - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis	Phase 3
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT02153320` - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers	Phase 1
Completed	`NCT00352963` - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).	Phase 3
Completed	`NCT03567382` - Arresting Vertical Transmission of Hepatitis B Virus	Phase 4
Not yet recruiting	`NCT04056728` - A Phase IV Study to Assess the Safety of EupentaTM Inj	Phase 4
Not yet recruiting	`NCT03604016` - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver	Phase 4
Completed	`NCT00753649` - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants	Phase 4
Recruiting	`NCT03027258` - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome	N/A
Completed	`NCT02540538` - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders	Phase 1
Terminated	`NCT02604199` - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection	Phase 2
Completed	`NCT02169674` - Hepatitis B Booster Study in Adolescence	Phase 4
Completed	`NCT02421666` - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV	N/A
Completed	`NCT01917357` - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject	Phase 3
Completed	`NCT01368497` - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection	Phase 3
Completed	`NCT01732354` - Study for Consolidation Period of Chronic Hepatitis B
Recruiting	`NCT01462981` - Cohort of Hepatitis B Research of Amsterdam	N/A

Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms